Diabetic Under 70 (Diabetics Below 70)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by AstraZeneca.
Recruitment status was Active, not recruiting
Information provided by:
First received: August 14, 2007
Last updated: January 21, 2009
Last verified: January 2009
A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <70mg/dl for such patients with very high risk) are screened. The doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.
Drug: Any cholesterol-lowering drug
||Time Perspective: Prospective
||Diabetic Under 70 (Diabetics Below 70)
| Estimated Enrollment:
| Study Start Date:
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.) who already receive cholesterol-lowering therapy
- Diabetics w/o CVD; diabetics who do not receive cholesterol-lowering therapy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00516204
|Vienna, Austria |
||Michael Roden, MD
||Chairs of the Austrian Diabetes Society
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 14, 2007
||January 21, 2009
||Not required for this study:
Keywords provided by AstraZeneca:
Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 22, 2014
Arterial Occlusive Diseases
Lipid Metabolism Disorders
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents